Glenmark Life Sciences Ltd
NSE:GLS
Balance Sheet
Balance Sheet Decomposition
Glenmark Life Sciences Ltd
Current Assets | 19.2B |
Cash & Short-Term Investments | 3.9B |
Receivables | 7.7B |
Other Current Assets | 7.6B |
Non-Current Assets | 9.3B |
Long-Term Investments | 111.1m |
PP&E | 9B |
Intangibles | 148.5m |
Other Non-Current Assets | 122.6m |
Current Liabilities | 4.4B |
Accounts Payable | 3.7B |
Accrued Liabilities | 120.3m |
Other Current Liabilities | 580.8m |
Non-Current Liabilities | 793.2m |
Long-Term Debt | 147.6m |
Other Non-Current Liabilities | 645.6m |
Balance Sheet
Glenmark Life Sciences Ltd
Mar-2019 | Mar-2020 | Mar-2021 | Mar-2022 | Mar-2023 | ||
---|---|---|---|---|---|---|
Assets | ||||||
Cash & Cash Equivalents |
21
|
100
|
1 156
|
5 122
|
2 838
|
|
Cash |
0
|
1
|
1
|
221
|
558
|
|
Cash Equivalents |
20
|
99
|
1 155
|
4 901
|
2 281
|
|
Total Receivables |
5 176
|
7 073
|
7 268
|
7 152
|
9 189
|
|
Accounts Receivables |
4 481
|
6 386
|
6 195
|
6 735
|
8 068
|
|
Other Receivables |
695
|
687
|
1 073
|
417
|
1 122
|
|
Inventory |
4 008
|
4 128
|
5 134
|
5 162
|
6 042
|
|
Other Current Assets |
102
|
300
|
432
|
210
|
434
|
|
Total Current Assets |
9 307
|
11 601
|
13 990
|
17 646
|
18 503
|
|
PP&E Net |
5 303
|
5 498
|
5 790
|
6 763
|
8 242
|
|
PP&E Gross |
5 303
|
5 498
|
5 790
|
6 763
|
8 242
|
|
Accumulated Depreciation |
187
|
475
|
773
|
1 130
|
1 516
|
|
Intangible Assets |
64
|
72
|
79
|
104
|
180
|
|
Note Receivable |
0
|
0
|
12
|
0
|
0
|
|
Long-Term Investments |
1
|
1
|
86
|
56
|
83
|
|
Other Long-Term Assets |
79
|
84
|
14
|
141
|
13
|
|
Total Assets |
14 754
N/A
|
17 256
+17%
|
19 971
+16%
|
24 710
+24%
|
27 021
+9%
|
|
Liabilities | ||||||
Accounts Payable |
1 874
|
2 035
|
2 226
|
3 244
|
4 095
|
|
Accrued Liabilities |
96
|
121
|
204
|
421
|
551
|
|
Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
|
Current Portion of Long-Term Debt |
0
|
0
|
0
|
17
|
23
|
|
Other Current Liabilities |
11 834
|
10 919
|
9 784
|
159
|
376
|
|
Total Current Liabilities |
13 804
|
13 075
|
12 214
|
3 840
|
5 044
|
|
Long-Term Debt |
0
|
0
|
0
|
12
|
171
|
|
Deferred Income Tax |
69
|
164
|
229
|
315
|
424
|
|
Total Liabilities |
13 873
N/A
|
13 239
-5%
|
12 443
-6%
|
4 167
-67%
|
5 639
+35%
|
|
Equity | ||||||
Common Stock |
20
|
20
|
20
|
245
|
245
|
|
Retained Earnings |
862
|
3 997
|
7 508
|
10 249
|
11 087
|
|
Additional Paid In Capital |
0
|
0
|
0
|
10 050
|
10 050
|
|
Total Equity |
881
N/A
|
4 017
+356%
|
7 527
+87%
|
20 543
+173%
|
21 382
+4%
|
|
Total Liabilities & Equity |
14 754
N/A
|
17 256
+17%
|
19 971
+16%
|
24 710
+24%
|
27 021
+9%
|
|
Shares Outstanding | ||||||
Common Shares Outstanding |
123
|
123
|
123
|
123
|
123
|